SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Jackie Robinson

PatientJackie Robinson
Date of birth1974-01-31
IdentifiersMRN HR-ML037-SYN; SSN (made up) 000-37-2286
Document date2026-08-26
AuthorMarcus Delacroix-Hale, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injections. [S]

History of Present Illness

Mr. Robinson returns four weeks after the lisinopril increase and empagliflozin, from his second eye injections this morning. Dr. Ostrowski-Lane reports the blood in the right eye is thinning and the macular swelling is less in both eyes. His heel blister is smaller with the dressings and the offloading shoe, and the podiatrist has seen him twice. Chest tightness is less since cardiology started metoprolol, and he has not used nitroglycerin. He has had no dizziness, genital itching or low blood sugar; fasting readings are 140 to 180 mg/dL. He has met the health center's grief counselor once and plans to continue. [S]

ElementDetail
EyesSecond injections today; hemorrhage thinning; less swelling
HeelSmaller; podiatry twice
ChestLess tightness on metoprolol
GlucoseFasting 140 to 180 mg/dL; no lows

Review of Systems

SystemResultFinding
EyesPositiveVision a little clearer
CardiovascularPositiveCalf pain after about a block; chest tightness less
GenitourinaryNegativeNo burning or genital itching
IntegumentaryPositiveHeel wound healing
PsychiatricPositiveGrieving; meeting a counselor

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1,000 mg oral tablet, one tablet twice daily with mealsOne tablet twice daily with mealsOral route2025-03-03activeS
Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70At bedtime, by the gradual titration planSubcutaneous route2025-03-03activeS
Lisinopril 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2025-03-03 to 2026-07-29completedS
Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake)One tablet dailyOral route2026-07-27activeS
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route2025-03-03activeS
Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutesAs needed for severe low blood sugarNasal route2026-07-27activeS
Metoprolol succinate extended-release 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-08-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the firstAs needed for chest pain, up to three dosesSublingual route2026-08-12activeS
Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eatingOne tablet daily, with sick-day rulesOral route2026-07-29activeS
Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparationOne tablet daily, with sick-day rulesOral route2026-07-29activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-26Body height180cmS
2026-08-26Body weight102.8kgS
2026-08-26Body mass index (BMI) [Ratio]31.7kg/m2S
2026-08-26Systolic blood pressure134mm[Hg]S
2026-08-26Diastolic blood pressure80mm[Hg]S
2026-08-26Heart rate60/minS
2026-08-26Respiratory rate16/minS
2026-08-26Body temperature36.6CelS
2026-08-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-26Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-08-26Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-08-26Creatinine [Mass/volume] in Serum or Plasma1.22mg/dL0.74-1.35 mg/dLNormalS
2026-08-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M71mL/min/{1.73_m2}90 or higher is normal; 60 to 89 is mildly decreased (G2)LowS
2026-08-26Ankle-brachial index0.68{ratio}1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormalLowS
2026-08-26Ankle-brachial index0.74{ratio}1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormalLowS

Physical Exam

Vital signs recorded on 2026-08-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 134/80, pulse 60; weight 102.8 kg
Right footHeel wound 1.2 by 1 cm, clean granulating base, no infection
FeetMonofilament absent in both forefeet, as at intake; pulses faint
VascularAnkle-brachial index 0.68 right and 0.74 left

Problems

ProblemClinical statusVerificationCodeProvenance
Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arrangedresolvedconfirmed H53.8S — Synthetic presenting finding, superseded by the retinal diagnosis two days later.
Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arrangedresolvedconfirmed R07.89S — Synthetic presenting finding, superseded by the coronary diagnosis after the stress test.
Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%)activeconfirmed E11.65S — Synthetic modern episode linked to his documented diabetes.
Proliferative diabetic retinopathy in both eyes with center-involving diabetic macular edema (central subfield 412 microns right, 468 left); best-corrected acuity 35 letters right and 56 letters leftactiveconfirmed E11.3513S — Synthetic retinal findings anchored to his documented loss of vision.
Vitreous hemorrhage in the right eye from proliferative retinopathy; retina attached on ultrasoundactiveconfirmed H43.11S — Synthetic finding.
Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg)activeconfirmed I12.9S — Synthetic modern episode linked to his documented high blood pressure.
Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79activeconfirmed E11.22S — Synthetic kidney findings.
Chronic kidney disease G2 A2activeconfirmed N18.2S — Synthetic kidney finding.
Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulsesactiveconfirmed E11.51S — Synthetic modern episode linked to the documented artery damage in his legs.
Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testingactiveconfirmed E11.42S — Synthetic modern episode linked to the documented nerve damage in his legs.
History of two mild strokes a year ago, without lasting weaknessactiveconfirmed Z86.73S — Synthetic modern coding of the documented strokes.
Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dLactiveconfirmed E78.5S — Synthetic laboratory finding.
Bereavement: his eldest son died in a car crash six weeks agoactiveconfirmed Z63.4S — Synthetic modern coding of a documented loss; grief is treated as grief, not as a disorder.
Coronary artery disease with stable angina on climbing stairs: a small reversible inferior perfusion defect on regadenoson stress imaging, ejection fraction 56%; medical therapy chosen with cardiologyactiveconfirmed I25.119S — Synthetic coronary diagnosis anchored to his documented heart disease; no heart attack is recorded before the episode.
Friction blister of the right heel from new shoes, unroofed, 2.5 by 2 cm, clean base, without infection, in a neuropathic foot with peripheral artery diseaseactiveconfirmed S90.821AS — Synthetic intercurrent problem at an unscheduled visit; it does not echo a documented event.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure (seated, two readings, large cuff)Every visitCompleted today134/80
ExaminationWeight and BMIEvery visitCompleted today102.8 kg
LaboratoryPotassium, creatinine and eGFRTwo to four weeks after starting or increasing an ACE inhibitor or SGLT2 inhibitor; then every 6 to 12 monthsCompleted todayFour weeks after the changes: sodium 138, potassium 4.8 mmol/L; creatinine 1.22 mg/dL; eGFR 71
ImagingAnkle-brachial indexAt diagnosis of peripheral artery disease; then with any change in symptoms or a woundCompleted today0.68 right and 0.74 left
ExaminationFoot inspection; comprehensive foot examinationEvery visit with loss of sensation; comprehensive examination yearlyCompleted todayHeel wound healing; no new breaks; sensation absent as before
ImagingRetina care: acuity, OCT, injections and laserMonthly at the retina clinic while treatingCompleted todaySecond injections today; hemorrhage thinning; less swelling (retina clinic report)
LaboratoryHemoglobin A1cEvery 3 months while not at goal or after a changeUp to dateNext at three months
Self-managementGlucose log and low blood sugar review (talking meter)Every visitCompleted todayFasting 140 to 180 mg/dL on the talking meter; no lows
LaboratoryLipid panel4 to 12 weeks after starting or changing a statin; then yearlyDueDue by twelve weeks after the atorvastatin increase
ExaminationAngina reviewEvery visitCompleted todayLess tightness on metoprolol; no nitroglycerin used
Medication safetyMedicine safety: low blood sugar, sick-day rules, genital infection, dizziness, costEvery visitCompleted todayNo low blood sugar, dizziness or genital infection
Self-managementLow-vision services and diabetes tools he can useWhen vision limits daily lifeCompleted todayLow-vision evaluation booked; talking meter in use; large-print plans

Goal progress:

Guideline basis: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023)

Follow-up: Preventive visit in four weeks. Third injections in four weeks and laser to the right eye when the blood clears. Three-month review in two months with the A1c, urine albumin, lipids and kidney function. Next scheduled visit 2026-09-21: periodic adult preventive visit. [S]